Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.
APOBEC
angiogenesis
hypoxia
immunity
mutational signatures
tumor mass dormancy
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2021
accepted:
17
06
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Tumor mass dormancy is the key intermediate step between immune surveillance and cancer progression, yet due to its transitory nature it has been difficult to capture and characterize. Little is understood of its prevalence across cancer types and of the mutational background that may favor such a state. While this balance is finely tuned internally by the equilibrium between cell proliferation and cell death, the main external factors contributing to tumor mass dormancy are immunological and angiogenic. To understand the genomic and cellular context in which tumor mass dormancy may develop, we comprehensively profiled signals of immune and angiogenic dormancy in 9,631 cancers from the Cancer Genome Atlas and linked them to tumor mutagenesis. We find evidence for immunological and angiogenic dormancy-like signals in 16.5% of bulk sequenced tumors, with a frequency of up to 33% in certain tissues. Mutations in the
Identifiants
pubmed: 34307377
doi: 10.3389/fcell.2021.698659
pmc: PMC8299471
doi:
Types de publication
Journal Article
Langues
eng
Pagination
698659Informations de copyright
Copyright © 2021 Wiecek, Jacobson, Lason and Secrier.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2020 Feb 7;11(1):790
pubmed: 32034147
Cancer Discov. 2019 Jul;9(7):837-851
pubmed: 30992279
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Cancer Cell. 2004 Aug;6(2):159-70
pubmed: 15324699
Front Immunol. 2019 May 21;10:1113
pubmed: 31164891
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Nat Rev Cancer. 2007 Nov;7(11):834-46
pubmed: 17957189
Nat Genet. 2013 Sep;45(9):970-6
pubmed: 23852170
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Br J Cancer. 2010 Jan 19;102(2):428-35
pubmed: 20087356
Nat Med. 2003 Jun;9(6):677-84
pubmed: 12778166
FEBS J. 2020 Nov 15;:
pubmed: 33190412
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Int J Oncol. 2012 Dec;41(6):1913-8
pubmed: 23076869
Oncogene. 2015 May 28;34(22):2823-35
pubmed: 25109329
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
Exp Mol Med. 2020 Apr;52(4):569-581
pubmed: 32300189
Nat Rev Cancer. 2013 Aug;13(8):585-95
pubmed: 23842645
Leukemia. 2014 Sep;28(9):1929-32
pubmed: 24840555
Annu Rev Genet. 2014;48:215-36
pubmed: 25292359
Epigenetics. 2013 Dec;8(12):1330-46
pubmed: 24135786
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32251515
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2532-2537
pubmed: 29463760
Mol Cancer Res. 2017 Apr;15(4):371-381
pubmed: 28031411
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Clin Cancer Res. 2013 Sep 1;19(17):4879-88
pubmed: 23820108
Annu Rev Pathol. 2013 Jan 24;8:79-103
pubmed: 22974238
Nat Cancer. 2020 Feb;1(2):249-263
pubmed: 32118208
Nat Biotechnol. 2019 Dec;37(12):1482-1492
pubmed: 31796933
Cancers (Basel). 2019 Aug 19;11(8):
pubmed: 31430951
Cancer Discov. 2015 Jul;5(7):704-12
pubmed: 26091828
Immunol Res. 2006;36(1-3):73-82
pubmed: 17337768
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
Sci Rep. 2019 May 9;9(1):7122
pubmed: 31073151
Sci Adv. 2019 May 22;5(5):eaaw4543
pubmed: 31131326
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3416-21
pubmed: 11248093
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Trends Cancer. 2019 Dec;5(12):762-765
pubmed: 31813453
Cell Rep. 2018 Jul 31;24(5):1105-1112.e5
pubmed: 30067968
Br Med J. 1954 Sep 11;2(4888):607-10
pubmed: 13190204
Oncotarget. 2015 Sep 15;6(27):23890-904
pubmed: 26287601
Immunity. 2004 Aug;21(2):137-48
pubmed: 15308095
J Natl Cancer Inst. 2006 Mar 1;98(5):316-25
pubmed: 16507828
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Genome Med. 2017 Jan 23;9(1):4
pubmed: 28115009
Exp Mol Med. 2009 Dec 31;41(12):849-57
pubmed: 19942820
Curr Mol Med. 2009 Nov;9(8):935-41
pubmed: 19925406
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Exp Med. 1972 Aug 1;136(2):261-76
pubmed: 5043412
Nat Med. 1995 Feb;1(2):149-53
pubmed: 7585012
Immunology. 2010 Apr;129(4):474-81
pubmed: 20201977
Breast Cancer Res. 2013 Dec 20;15(6):321
pubmed: 24359585
Oncogene. 2002 Apr 11;21(16):2513-24
pubmed: 11971186
Cancer Res. 2007 Apr 1;67(7):3441-9
pubmed: 17409455
Nature. 1997 Sep 18;389(6648):300-5
pubmed: 9305847
Cancer Cell. 2002 Jun;1(5):445-57
pubmed: 12124174
J Gen Virol. 2008 Mar;89(Pt 3):722-730
pubmed: 18272764
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Biochemistry. 1995 Apr 18;34(15):5011-7
pubmed: 7711023
J Biol Chem. 2002 May 17;277(20):18206-14
pubmed: 11880381
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
F1000Res. 2020 Jun 22;9:
pubmed: 32595946
Int J Oncol. 2016 Jun;48(6):2339-48
pubmed: 27082853
Nat Rev Cancer. 2020 Jul;20(7):398-411
pubmed: 32488200
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S149-51
pubmed: 12586108
Cancer Res. 2003 Apr 1;63(7):1684-95
pubmed: 12670923
Int J Mol Sci. 2019 Sep 03;20(17):
pubmed: 31484342
Nat Struct Mol Biol. 2010 Feb;17(2):222-9
pubmed: 20062055
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
DNA Repair (Amst). 2019 Nov;83:102700
pubmed: 31563041
Nat Commun. 2017 Mar 20;8:14728
pubmed: 28317845
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Nat Biotechnol. 2019 Apr;37(4):367-369
pubmed: 30877282
Cancer Res. 2019 Dec 15;79(24):6238-6246
pubmed: 31641033
Cancer Res. 2015 Sep 15;75(18):3936-45
pubmed: 26208904
Front Immunol. 2014 Jun 17;5:276
pubmed: 24987392
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Eur Urol. 2004 Aug;46(2):200-8
pubmed: 15245814
Int J Cancer. 2015 Jun 15;136(12):2967-72
pubmed: 25403517
Oncogenesis. 2018 Jan 24;7(1):10
pubmed: 29362402
Front Pharmacol. 2019 Jun 04;10:624
pubmed: 31214035
Front Oncol. 2013 Nov 07;3:244
pubmed: 24224156
Oncogene. 2018 Jul;37(29):3924-3936
pubmed: 29695832
Mol Cell. 2021 Apr 15;81(8):1698-1714.e6
pubmed: 33626321
Science. 1996 May 3;272(5262):719-22
pubmed: 8614832
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Commun. 2018 May 10;9(1):1857
pubmed: 29748584
Cancer Cell. 2013 Mar 18;23(3):274-6
pubmed: 23518346
Immunol Rev. 2017 May;277(1):76-89
pubmed: 28462525
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Cancer Lett. 2014 Apr 28;346(1):104-13
pubmed: 24374017
Clin Cancer Res. 2016 Sep 15;22(18):4746-55
pubmed: 27016308
Front Oncol. 2019 Jun 26;9:498
pubmed: 31297335
Trends Cancer. 2021 Apr;7(4):309-322
pubmed: 33536158
Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109
pubmed: 11900986
J Leukoc Biol. 2008 Oct;84(4):988-93
pubmed: 18515327
Trends Pharmacol Sci. 2017 Aug;38(8):669-686
pubmed: 28602395
J Thromb Haemost. 2003 Aug;1(8):1683-7
pubmed: 12911578
Nat Genet. 2013 Sep;45(9):977-83
pubmed: 23852168
Pigment Cell Melanoma Res. 2016 Jan;29(1):27-42
pubmed: 26514653
J Cell Biol. 1999 Oct 4;147(1):89-104
pubmed: 10508858
Nature. 2000 Nov 16;408(6810):307-10
pubmed: 11099028
Cancer Res. 2006 Feb 1;66(3):1702-11
pubmed: 16452230
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
PLoS One. 2014 Aug 28;9(8):e105372
pubmed: 25166211
Genes Cancer. 2011 Dec;2(12):1117-33
pubmed: 22866203
Cancer Res. 2001 Dec 15;61(24):8664-7
pubmed: 11751382
Genome Res. 2019 Jul;29(7):1067-1077
pubmed: 31221724
Nat Genet. 2019 Feb;51(2):308-318
pubmed: 30643250
Nat Cancer. 2020 May;1(5):546-561
pubmed: 32803172
Oral Oncol. 2019 Sep;96:140-147
pubmed: 31422205
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346